Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigations

Expert Review of Proteomics

Volumn 12, Issue 5, 2015, Pages 499-517

  Önder, Özlem ^a,b   Sidoli, Simone ^b   Carroll, Martin ^a   Garcia, Benjamin A ^b  

^a Division of Hematology Oncology   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cancer; chromatin; epigenetics; histone; histone variants; mass spectrometry; post translational modifications; proteomics; translational medicine

Indexed keywords

CHROMOSOME CONDENSATION; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE EXPRESSION; GENETIC VARIABILITY; GLOBAL CHANGE; HISTONE MODIFICATION; HUMAN; INVESTIGATIVE PROCEDURES; MASS SPECTROMETRY; NEOPLASM; NONHUMAN; PROTEOMICS; REVIEW; ANIMAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENETIC EPIGENESIS; HISTONE CODE; PROCEDURES; TRANSLATIONAL RESEARCH;

ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE CODE; HUMANS; MASS SPECTROMETRY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84942422655     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2015.1084231     Document Type: Review

References (148)

1. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4 (2): 143-53
2. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3 (4): 253-66
3. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Gent 2006; 15 (Spec No 1): R17-29
4. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293 (5532): 1074-80
5. Luger K, Mader AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389 (6648): 251-60
6. van Attikum H, Gasser SM. Crosstalk between histone modifications during the DNA damage response. Trends Cell Biol 2009; 19 (5): 207-17
7. Fernandez-Capetillo O, Mahadevaiah SK, Celeste A, et al. H2AX is required for chromatin remodeling and inactivation of sex chromosomes in male mouse meiosis. Dev Cell 2003; 4 (4): 497-508
8. Turner JM, Mahadevaiah SK, Fernandez-Capetillo O, et al. Silencing of unsynapsed meiotic chromosomes in the mouse. Nat Genet 2005; 37 (1): 41-7
9. Hake SB, Allis CD. Histone H3 variants and their potential role in indexing mammalian genomes: the "H3 barcode hypothesis". Proc Natl Acad Sci USA 2006; 103 (17): 6428-35
10. Santaguida S, Musacchio A. The life and miracles of kinetochores. EMBO J 2009; 28 (17): 2511-31
11. Cosgrove MS. Histone proteomics and the epigenetic regulation of nucleosome mobility. Exp Rev Proteomics 2007; 4 (4): 465-78
12. Shogren-Knaak M, Ishii H, Sun JM, et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006; 311 (5762): 844-7
13. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28 (10): 1069-78
14. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301 (5895): 89-92
15. Lee JV, Carrer A, Shah S, et al. Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab 2014; 20 (2): 306-19
16. Alabert C, Groth A. Chromatin replication and epigenome maintenance. Nat Rev Mol Cell Biol 2012; 13 (3): 153-67
17. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150 (1): 12-27
18. Baylin SB, Hoppener JW, de Bustros A, et al. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res 1986; 46 (6): 2917-22
19. Greger V, Passarge E, Hopping W, et al. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Human Genet 1989; 83 (2): 155-8
20. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11 (10): 726-34
21. Li W, Nagaraja S, Delcuve GP, et al. Effects of histone acetylation, ubiquitination and variants on nucleosome stability. Biochem J 1993; 296 (Pt 3): 737-44
22. Shiio Y, Eisenman RN. Histone sumoylation is associated with transcriptional repression. Proc Natl Acad Sci USA 2003; 100 (23): 13225-30
23. Chen Y, Sprung R, Tang Y, et al. Lysine propionylation and butyrylation are novel post-Translational modifications in histones. Mol Cellular Proteomics: MCP 2007; 6 (5): 812-19
24. Jiang T, Zhou X, Taghizadeh K, et al. N-formylation of lysine in histone proteins as a secondary modification arising from oxidative DNA damage. Proc Natl Acad Sci USA 2007; 104 (1): 60-5
25. Tan M, Luo H, Lee S, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011; 146 (6): 1016-28
26. Boulikas T. DNA strand breaks alter histone ADP-ribosylation. Proc Natl Acad Sci USA 1989; 86 (10): 3499-503
27. Sakabe K, Wang Z, Hart GW. Beta-N-Acetylglucosamine (O-GlcNAc) is part of the histone code. Proc Natl Acad Sci USA 2010; 107 (46): 19915-20
28. Sidoli S, Cheng L, Jensen ON. Proteomics in chromatin biology and epigenetics: Elucidation of post-Translational modifications of histone proteins by mass spectrometry. J Proteomics 2012; 75 (12): 3419-33
29. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403 (6765): 41-5
30. Hunter T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mole Cell 2007; 28 (5): 730-8
31. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37 (4): 391-400
32. Dhalluin C, Carlson JE, Zeng L, et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999; 399 (6735): 491-6
33. van Zutven LJ, Onen E, Velthuizen SC, et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer 2006; 45 (5): 437-46
34. Wang GG, Song J, Wang Z, et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 2009; 459 (7248): 847-51
35. Reader JC, Meekins JS, Gojo I, Ning Y. A novel NUP98-PHF23 fusion resulting from a cryptic translocation t(11;17)(p15;p13) in acute myeloid leukemia. Leukemia 2007; 21 (4): 842-4
36. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 2007; 25 (1): 15-30
37. Van Aller GS, Reynoird N, Barbash O, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics 2012; 7 (4): 340-3
38. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469 (7330): 343-9
39. Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23 (5): 677-92
40. Shen X, Liu Y, Hsu YJ, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32 (4): 491-502
41. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24 (2): 268-73
42. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419 (6907): 624-9
43. Wang H, Albadine R, Magheli A, et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urologic Oncol 2012; 30 (4): 428-33
44. Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013; 340 (6134): 857-61
45. De Koning L, Corpet A, Haber JE, Almouzni G. Histone chaperones: an escort network regulating histone traffic. Nat Struct Mol Biol 2007; 14 (11): 997-1007
46. Groth A, Rocha W, Verreault A, Almouzni G. Chromatin challenges during DNA replication and repair. Cell 2007; 128 (4): 721-33
47. Albig W, Kioschis P, Poustka A, et al. Human histone gene organization: nonregular arrangement within a large cluster. Genomics 1997; 40 (2): 314-22
48. Pusarla RH, Bhargava P. Histones in functional diversification. Core histone variants. FEBS J 2005; 272 (20): 5149-68
49. Dhillon N, Oki M, Szyjka SJ, et al. H2A.Z functions to regulate progression through the cell cycle. Mol Cell Biol 2006; 26 (2): 489-501
50. Xu Y, Ayrapetov MK, Xu C, et al. Histone H2A.Z controls a critical chromatin remodeling step required for DNA double-strand break repair. Mol Cell 2012; 48 (5): 723-33
51. Larochelle M, Gaudreau L. H2A.Z has a function reminiscent of an activator required for preferential binding to intergenic DNA. EMBO J 2003; 22 (17): 4512-22
52. Marques M, Laflamme L, Gervais AL, Gaudreau L. Reconciling the positive and negative roles of histone H2A.Z in gene transcription. Epigenetics 2010; 5 (4): 267-72
53. ODonnell A, Yang SH, Sharrocks AD. PARP1 orchestrates variant histone exchange in signal-mediated transcriptional activation. EMBO Rep 2013; 14 (12): 1084-91
54. Sarcinella E, Zuzarte PC, Lau PN, et al. Monoubiquitylation of H2A.Z distinguishes its association with euchromatin or facultative heterochromatin. Mol Cell Biol 2007; 27 (18): 6457-68
55. Meneghini MD, Wu M, Madhani HD. Conserved histone variant H2A.Z protects euchromatin from the ectopic spread of silent heterochromatin. Cell 2003; 112 (5): 725-36
56. Rangasamy D, Greaves I, Tremethick DJ. RNA interference demonstrates a novel role for H2A.Z in chromosome segregation. Nat Struct Mol Biol 2004; 11 (7): 650-5
57. Adam M, Robert F, Larochelle M, Gaudreau L. H2A.Z is required for global chromatin integrity and for recruitment of RNA polymerase II under specific conditions. Mol Cell Biol 2001; 21 (18): 6270-9
58. Henikoff S, Smith MM. Histone variants and epigenetics. Cold Spring Harb Perspect Biol 2015; 7 (1): a019364
59. Dunican DS, McWilliam P, Tighe O, et al. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene 2002; 21 (20): 3253-7
60. Baptista T, Graca I, Sousa EJ, et al. Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer. Oncotarget 2013; 4 (10): 1673-85
61. Kim K, Punj V, Choi J, et al. Gene dysregulation by histone variant H2A.Z in bladder cancer. Epigenet Chromat 2013; 6 (1): 34
62. Hua S, Kallen CB, Dhar R, et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 2008; 4: 188
63. Kapoor A, Goldberg MS, Cumberland LK, et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 2010; 468 (7327): 1105-9
64. Brandt WF, von Holt C. The determination of the primary structure of histone F3 from chicken erythrocytes by automatic Edman degradation. 2. Sequence analysis of histone F3. Eur J Biochem 1974; 46 (2): 419-29
65. Chicoine LG, Schulman IG, Richman R, et al. Nonrandom utilization of acetylation sites in histones isolated from Tetrahymena. Evidence for functionally distinct H4 acetylation sites. J Biol Chem 1986; 261 (3): 1071-6
66. Bock I, Dhayalan A, Kudithipudi S, et al. Detailed specificity analysis of antibodies binding to modified histone tails with peptide arrays. Epigenet 2011; 6 (2): 256-63
67. Cheung P. Generation and characterization of antibodies directed against di-modified histones, and comments on antibody and epitope recognition. Methods Enzymol 2004; 376: 221-34
68. Byrum SD, Raman A, Taverna SD, Tackett AJ. ChAP-MS: a method for identification of proteins and histone posttranslational modifications at a single genomic locus. Cell Rep 2012; 2 (1): 198-205
69. Soldi M, Bonaldi T. The ChroP approach combines ChIP and mass spectrometry to dissect locus-specific proteomic landscapes of chromatin. J Visualized Exp JoVE 2014; 86
70. Ji X, Dadon DB, Abraham BJ, et al. Chromatin proteomic profiling reveals novel proteins associated with histone-marked genomic regions. Proc Natl Acad Sci USA 2015; 112 (12): 3841-6
71. Smith LM, Kelleher NL,; Consortium for Top Down P. Proteoform: a single term describing protein complexity. Nat Methods 2013; 10 (3): 186-7
72. Zhang K, Williams KE, Huang L, et al. Histone acetylation and deacetylation: identification of acetylation and methylation sites of HeLa histone H4 by mass spectrometry. Mol Cell Proteomics 2002; 1 (7): 500-8
73. Zhang K, Tang H, Huang L, et al. Identification of acetylation and methylation sites of histone H3 from chicken erythrocytes by high-Accuracy matrix-Assisted laser desorption ionization-Time-of-flight, matrix-Assisted laser desorption ionization-postsource decay, and nanoelectrospray ionization tandem mass spectrometry. Anal Biochem 2002; 306 (2): 259-69
74. Garcia BA, Mollah S, Ueberheide BM, et al. Chemical derivatization of histones for facilitated analysis by mass spectrometry. Nat Protoc 2007; 2 (4): 933-8
75. Smith CM. Quantification of acetylation at proximal lysine residues using isotopic labeling and tandem mass spectrometry. Methods 2005; 36 (4): 395-403
76. Smith CM, Gafken PR, Zhang Z, et al. Mass spectrometric quantification of acetylation at specific lysines within the amino-Terminal tail of histone H4. Anal Biochem 2003; 316 (1): 23-33
77. Karczmarski J, Rubel T, Paziewska A, et al. Histone H3 lysine 27 acetylation is altered in colon cancer. Clin Proteomics 2014; 11 (1): 24
78. Cuomo A, Moretti S, Minucci S, Bonaldi T. SILAC-based proteomic analysis to dissect the "histone modification signature" of human breast cancer cells. Amino Acids 2011; 41 (2): 387-99
79. Jaffe JD, Wang Y, Chan HM, et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet 2013; 45 (11): 1386-91
80. Beck HC, Nielsen EC, Matthiesen R, et al. Quantitative proteomic analysis of post-Translational modifications of human histones. Mol Cell Proteomics 2006; 5 (7): 1314-25
81. Drogaris P, Villeneuve V, Pomies C, et al. Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation. Scientific Reports 2012; 2: 220
82. Drogaris P, Wurtele H, Masumoto H, et al. Comprehensive profiling of histone modifications using a label-free approach and its applications in determining structure-function relationships. Anal Chem 2008; 80 (17): 6698-707
83. Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002; 1 (5): 376-86
84. Scharf AN, Barth TK, Imhof A. Establishment of histone modifications after chromatin assembly. Nucliec Acids Res 2009; 37 (15): 5032-40
85. Zee BM, Levin RS, Xu B, et al. In vivo residue-specific histone methylation dynamics. J Biol Chem 2010; 285 (5): 3341-50
86. Leroy G, Dimaggio PA, Chan EY, et al. A quantitative atlas of histone modification signatures from human cancer cells. Epigenetics Chromatin 2013; 6 (1): 20
87. Chang B, Chen Y, Zhao Y, Bruick RK. JMJD6 is a histone arginine demethylase. Science 2007; 318 (5849): 444-7
88. Tu S, Bulloch EM, Yang L, et al. Identification of histone demethylases in Saccharomyces cerevisiae. J Biol Chem 2007; 282 (19): 14262-71
89. Kelleher NL. Top-down proteomics. Anal Chem 2004; 76 (11): 197A-203A
90. Loo JA, Edmonds CG, Smith RD. Primary sequence information from intact proteins by electrospray ionization tandem mass spectrometry. Science 1990; 248 (4952): 201-4
91. Ginter JM, Zhou F, Johnston MV. Generating protein sequence tags by combining cone and conventional collision induced dissociation in a quadrupole time-of-flight mass spectrometer. J Am Soc Mass Spectrum 2004; 15 (10): 1478-86
92. Zubarev RAK, McLafferty FW. Electron capture dissociation of multiply charged protein cations. a nonergodic process. J Am Chem Soc 1998; 120: 3265-6
93. Syka JE, Coon JJ, Schroeder MJ, et al. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci USA 2004; 101 (26): 9528-33
94. Compton PD, Strukl JV, Bai DL, et al. Optimization of electron transfer dissociation via informed selection of reagents and operating parameters. Anal Chem 2012; 84 (3): 1781-5
95. Udeshi ND, Shabanowitz J, Hunt DF, Rose KL. Analysis of proteins and peptides on a chromatographic timescale by electron-Transfer dissociation MS. FEBS J 2007; 274 (24): 6269-76
96. Banks GC, Deterding LJ, Tomer KB, Archer TK. Hormone-mediated dephosphorylation of specific histone H1 isoforms. J Biol Chem 2001; 276 (39): 36467-73
97. Thomas CE, Kelleher NL, Mizzen CA. Mass spectrometric characterization of human histone H3: a birds eye view. J Proteome Res 2006; 5 (2): 240-7
98. Boyne MT 2nd, Pesavento JJ, Mizzen CA, Kelleher NL. Precise characterization of human histones in the H2A gene family by top down mass spectrometry. J Proteome Res 2006; 5 (2): 248-53
99. Siuti N, Roth MJ, Mizzen CA, et al. Gene-specific characterization of human histone H2B by electron capture dissociation. J Proteome Res 2006; 5 (2): 233-9
100. Pesavento JJ, Mizzen CA, Kelleher NL. Quantitative analysis of modified proteins and their positional isomers by tandem mass spectrometry: human histone H4. Anal Chem 2006; 78 (13): 4271-80
101. Vellaichamy A, Tran JC, Catherman AD, et al. Size-sorting combined with improved nanocapillary liquid chromatography-mass spectrometry for identification of intact proteins up to 80 kDa. Anal Chem 2010; 82 (4): 1234-44
102. Bloom GC, Eschrich S, Zhou JX, et al. Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int J Cancer 2007; 120 (4): 769-75
103. Zhou G, Li H, DeCamp D, et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002; 1 (2): 117-24
104. Sarg B, Faserl K, Kremser L, et al. Comparing and combining capillary electrophoresis electrospray ionization mass spectrometry and nano-liquid chromatography electrospray ionization mass spectrometry for the characterization of post-Translationally modified histones. Mol Cell Proteomics 2013; 12 (9): 2640-56
105. Meng F, Cargile BJ, Patrie SM, et al. Processing complex mixtures of intact proteins for direct analysis by mass spectrometry. Anal Chem 2002; 74 (13): 2923-9
106. Taverna SD, Ueberheide BM, Liu Y, et al. Long-distance combinatorial linkage between methylation and acetylation on histone H3 N termini. Proc Natl Acad Sci USA 2007; 104 (7): 2086-91
107. Garcia BA. What does the future hold for Top Down mass spectrometry? J Am Soc Mass Spectrum 2010; 21 (2): 193-202
108. Cannon J, Lohnes K, Wynne C, et al. High-Throughput middle-down analysis using an orbitrap. J Proteome Res 2010; 9 (8): 3886-90
109. Swatkoski S, Gutierrez P, Wynne C, et al. Evaluation of microwave-Accelerated residue-specific acid cleavage for proteomic applications. J Proteome Res 2008; 7 (2): 579-86
110. Lindner H, Sarg B, Meraner C, Helliger W. Separation of acetylated core histones by hydrophilic-interaction liquid chromatography. J Chromatogr A 1996; 743 (1): 137-44
111. Mant CT, Hodges RS. Mixed-mode hydrophilic interaction/cation-exchange chromatography (HILIC/CEX) of peptides and proteins. J Sep Sci 2008; 31 (15): 2754-73
112. Garcia BA, Pesavento JJ, Mizzen CA, Kelleher NL. Pervasive combinatorial modification of histone H3 in human cells. Nat Methods 2007; 4 (6): 487-9
113. Jung HR, Sidoli S, Haldbo S, et al. Precision mapping of coexisting modifications in histone H3 tails from embryonic stem cells by ETD-MS/MS. Anal Chem 2013; 85 (17): 8232-9
114. Sidoli S, Schwammle V, Ruminowicz C, et al. Middle-down hybrid chromatography/tandem mass spectrometry workflow for characterization of combinatorial post-Translational modifications in histones. Proteomics 2014; 14 (19): 2200-11
115. Young NL, DiMaggio PA, Plazas-Mayorca MD, et al. High throughput characterization of combinatorial histone codes. Mol Cell Proteomics 2009; 8 (10): 2266-84
116. Tran JC, Zamdborg L, Ahlf DR, et al. Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature 2011; 480 (7376): 254-8
117. Gault J, Malosse C, Machata S, et al. Complete posttranslational modification mapping of pathogenic Neisseria meningitidis pilins requires top-down mass spectrometry. Proteomics 2014; 14 (10): 1141-51
118. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349 (21): 2042-54
119. Delpu Y, Cordelier P, Cho WC, Torrisani J. DNA methylation and cancer diagnosis. Int J Mol Sci 2013; 14 (7): 15029-58
120. Powrozek T, Krawczyk P, Kucharczyk T, Milanowski J. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol 2014; 31 (4): 917
121. Wei SH, Balch C, Paik HH, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006; 12 (9): 2788-94
122. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435 (7046): 1262-6
123. Liu TF, McCall CE. Deacetylation by SIRT1 Reprograms Inflammation and Cancer. Genes Cancer 2013; 4 (3-4): 135-47
124. Barber MF, Michishita-Kioi E, Xi Y, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012; 487 (7405): 114-18
125. Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009; 174 (5): 1619-28
126. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-Alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391 (6669): 815-18
127. Fenrick R, Hiebert SW. Role of histone deacetylases in acute leukemia. J Cell Biochem 1998 (Suppl 30-31): 194-202
128. Falk H, Connor T, Yang H, et al. An efficient high-Throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets. J Biomol Screen 2011; 16 (10): 1196-205
129. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358 (11): 1148-59
130. Chopra M, Bohlander SK. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases. Cancer Genet 2014; 208 (5): 192-205
131. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119 (7): 941-53
132. Hayami S, Kelly JD, Cho HS, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011; 128 (3): 574-86
133. Katz TA, Vasilatos SN, Harrington E, et al. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. Breast Cancer Res Treat 2014; 146 (1): 99-108
134. Vardabasso C, Hasson D, Ratnakumar K, et al. Histone variants: emerging players in cancer biology. Cell Mol Life Sci 2014; 71 (3): 379-404
135. Campbell RM, Tummino PJ. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest 2014; 124 (1): 64-9
136. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012; 6 (6): 579-89
137. Friend C, Scher W, Holland JG, Sato T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 1971; 68 (2): 378-82
138. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95 (6): 3003-7
139. DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother 2015; 16 (1): 95-106
140. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8 (11): 890-6
141. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-Activating mutations. Nature 2012; 492 (7427): 108-12
142. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012; 109 (52): 21360-5
143. Xu B, On DM, Ma A, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 2015; 125 (2): 346-57
144. Christophorou MA, Castelo-Branco G, Halley-Stott RP, et al. Citrullination regulates pluripotency and histone H1 binding to chromatin. Nature 2014; 507 (7490): 104-8
145. Dai L, Peng C, Montellier E, et al. Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark. Nat Chem Biol 2014; 10 (5): 365-70
146. Tessarz P, Santos-Rosa H, Robson SC, et al. Glutamine methylation in histone H2A is an RNA-polymerase-I-dedicated modification. Nature 2014; 505 (7484): 564-8
147. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics 2012; 11 (6): O111-016717
148. Sidoli S, Lin S, Xiong L, et al. SWATH analysis for characterization and quantification of histone post-Translational modifications. Mol Cell Proteomics 2015. [Epub ahead of print]